ArticleBioinformation2026
Comparative evaluation of hrHPV DNA testing, cervical cytology and histopathology for cervical precancer detection.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a major public health challenge in India, driven primarily by persistent high-risk HPV infection. Hence, this prospective study evaluated hrHPV DNA testing, cervical cytology and co-testing in 400 symptomatic women, using histopathology as the gold standard for CIN2+ detection. HPV DNA testing showed the highest sensitivity (90%) and diagnostic accuracy (63.8%) compared with cytology and co-testing, while ROC analysis confirmed its superior performance (AUC 0.75). HPV16 was the predominant genotype, followed by HPV18, HPV52 and HPV58, together accounting for most high-grade lesions. Thus, we show HPV DNA testing as a more reliable primary screening method than cytology in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.